Drug Trial Radar · NCT01178112
Trientine and Carboplatin in Advanced Malignancies
Last checked: Nov 20, 2026Latest source record: Nov 18, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Jul 2010
Primary completion
Aug 2014
Study completion Aug 2014
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 9, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical research study is to find the highest tolerable dose of the combination of trientine and carboplatin that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.
Conditions
- Advanced Cancers
Interventions
TrientineDrug
Starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days.
CarboplatinDrug
Starting dose area under curve (AUC) 4 by vein over two hours on day 1, and once every 28 days.
Trientine MTDDrug
Maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2.
Carboplatin MTDDrug
Maximum tolerated dose found in MTD Dose Escalation Group
PK TestingOther
Blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD) of Carboplatin with TrientineTime frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Texas MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.